Log in

Relevant bibliographies by topics / In-transit metastases / Journal articles

To see the other types of publications on this topic, follow the link: In-transit metastases.

Journal articles on the topic 'In-transit metastases'

Author: Grafiati

Published: 5 September 2021

Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'In-transit metastases.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kocatüurk, Emek, Pelin Kuteyla Ülkümen, Utkan Kizitaç, Tülin Yüksel, Ayşle Seza Kunter, and Selma Şlengiz Erhan. "In-Transit Metastasis from Primary Cutaneous Squamous Cell Carcinoma in a Nonimmunosuppressed Patient." Journal of Cutaneous Medicine and Surgery 19, no. 2 (2015): 167–70. http://dx.doi.org/10.2310/7750.2014.14047.

Full text

Abstract:

Background In-transit metastases are dermal and subcutanous metastatic foci located between the tumor and the closest regional lymph node. Although in-transit metastasis has been commonly described for malignant melanoma, there have been some reports of in-transit metastases arising from primary cutaneous malignancies. The risk of development of in-transit metastases is higher in patients with high-risk squamous cell carcinoma. Case Report We present a case of in-transit metastasis in a nonimmunosuppressed patient with a primary cutaneous squamous cell carcinoma.

APA, Harvard, Vancouver, ISO, and other styles

2

Lejeune, F. J. "In transit metastases." European Journal of Cancer 37 (April 2001): S252. http://dx.doi.org/10.1016/s0959-8049(01)81423-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Di Altobrando, Ambra, Federica Scarfì, Cosimo Misciali, Annalisa Patrizi, and Emi Dika. "In‐transit melanoma metastases." International Journal of Dermatology 58, no. 7 (2019): 844–45. http://dx.doi.org/10.1111/ijd.14377.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Costa, Sergio Renato Pais, Sergio Henrique Couto Horta, and Alexandre Cruz Henriques. "Popliteal lymphadenectomy for treating metastatic melanoma: case report." Sao Paulo Medical Journal 126, no. 4 (2008): 232–35. http://dx.doi.org/10.1590/s1516-31802008000400009.

Full text

Abstract:

CONTEXT: Regional lymph node involvement in patients with malignant melanomas has been associated with poor prognosis. In-transit metastases also lead to poor long-term survival. Whereas for nodal disease only regional lymphadenectomy offers adequate locoregional control, for in-transit metastasis both local excision and isolated limb perfusion with chemotherapy plus tumor necrosis factor-alpha can be used for disease control. In cases of tumors located in the distal region of the legs, the lymphatic dissemination most commonly observed is to the inguinal chain. Consequently, therapeutic ingui

APA, Harvard, Vancouver, ISO, and other styles

5

Queiroz, Marcello Moro, Eduardo Bertolli, Francisco Aparecido Belfort, and Rodrigo Ramella Munhoz. "Management of In-Transit Metastases." Current Oncology Reports 24, no. 5 (2022): 573–83. http://dx.doi.org/10.1007/s11912-022-01216-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Trapeznikov, N., and L. Demidov. "Management of in-transit metastases." Melanoma Research 3, no. 1 (1993): 31. http://dx.doi.org/10.1097/00008390-199303000-00106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Al-Mondhiry, Jafar, Chelsea Stahl, Suraj S. Venna, and Sekwon Jang. "Detection of ctDNA in patients with stage III cutaneous melanoma with satellite/in-transit or nodal metastases." Journal of Clinical Oncology 41, no. 16_suppl (2023): e21559-e21559. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21559.

Full text

Abstract:

e21559 Background: Circulating tumor DNA (ctDNA) has emerged as a biomarker to monitor disease status in cancer patients. Limited data exists on the sensitivity of ctDNA for detection of satellite/in-transit or nodal metastases in melanoma. Methods: We conducted a retrospective study of stage III cutaneous melanomas with clinically detected satellite/in-transit and/or lymph node metastases who underwent ctDNA analysis using an mPCR-NGS-based ctDNA assay ("Signatera") prior to surgery or systemic therapy at Inova Schar Cancer Institute. Results: ctDNA was detected in 4 of 14 patients including

APA, Harvard, Vancouver, ISO, and other styles

8

Biswas, Bivas, Deepak Dabkara, and Sandip Ganguly. "In-transit metastases from malignant melanoma." National Medical Journal of India 30, no. 5 (2017): 297. http://dx.doi.org/10.4103/0970-258x.234405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lee, Yunjae, Dongkyu Lee, Hyeonjung Yeo, Hannara Park, and Hyochun Park. "Extraordinarily aggressive cutaneous sarcomatoid squamous cell carcinoma of the face: a case report." Archives of Craniofacial Surgery 23, no. 2 (2022): 77–82. http://dx.doi.org/10.7181/acfs.2022.00059.

Full text

Abstract:

Sarcomatoid squamous cell carcinoma (SSCC), a biphasic malignant tumor consisting of atypical squamous epithelial and mesenchymal elements mixed with epithelioid and spindle cells, is a variant of squamous cell carcinoma. Cutaneous SSCC is very rare and aggressive and has a poor prognosis. Here, we report a case of cutaneous SSCC with satellites and in-transit metastases. A 79-year-old woman presented with a protruding mass on the left temporal area sized 1.2× 1.0 cm. The punch biopsy report indicated keratoacanthoma or well-differentiated squamous cell carcinoma. The size of the tumor increas

APA, Harvard, Vancouver, ISO, and other styles

10

Mikkelsen, Joachim, Anne Lene Hagen Wagenblast, Nille Behrendt, and Jørgen Lock-Andersen. "Melanoma in situ with in-transit metastases." JPRAS Open 11 (March 2017): 37–42. http://dx.doi.org/10.1016/j.jpra.2017.01.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Kumar, NSudhir, and ShilpaY Krishnegowda. "In-transit metastases of acral lentiginous melanoma." Pigment International 2, no. 1 (2015): 51. http://dx.doi.org/10.4103/2349-5847.159398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Pararajasingam, Abirami, and Richard Goodwin. "In-transit metastases: the migration of melanoma." British Journal of Hospital Medicine 81, no. 9 (2020): 1. http://dx.doi.org/10.12968/hmed.2020.0202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Letcă, Alina Florentina, Loredana Ungureanu, Lavinia Elena Grigore, Liliana Rogojan, and Rodica Cosgarea. "Melanoma with regression and in-transit metastasis." Medicine and Pharmacy Reports 89, no. 1 (2016): 165–68. http://dx.doi.org/10.15386/cjmed-525.

Full text

Abstract:

Introduction. Melanoma is an aggressive tumor with an increasing incidence worldwide. In-transit metastases represent a unique pattern of dissemination.Case report. We report the case of a 42-year-old woman who presented with two lesions on the left latero-cervical region: a pigmented macule with irregular borders and colors and a firm, dome-shaped 5 mm nodule with an erythematous base and a black crust on top, at the periphery of the first lesion. The clinical picture supported the diagnosis of melanoma with in-transit metastasis, but the histopathology examination raised, initially, the prob

APA, Harvard, Vancouver, ISO, and other styles

14

Russano, Francesco, Paolo Del Fiore, Fortunato Cassalia, et al. "Do Tumor SURVIVIN and MDM2 Expression Levels Correlate with Treatment Response and Clinical Outcome in Isolated Limb Perfusion for In-Transit Cutaneous Melanoma Metastases?" Journal of Personalized Medicine 13, no. 12 (2023): 1657. http://dx.doi.org/10.3390/jpm13121657.

Full text

Abstract:

Isolated limb perfusion (ILP) involves the local administration of high doses of anticancer drugs into a limb affected by unresectable locally advanced tumors (with special regard to in-transit melanoma metastases), minimizing systemic side effects. Tumor response to anticancer drugs may depend on the expression of apoptosis-related genes, such as SURVIVIN and MDM2. This retrospective cohort study investigated the association between tumor SURVIVIN and MDM2 expression levels and treatment response or clinical outcomes in patients undergoing ILP for in-transit melanoma metastases. The study coh

APA, Harvard, Vancouver, ISO, and other styles

15

Padmavathy, L., LLakshmana Rao, Sylvester, MDhana Lakshmi, and N. Ethirajan. "In-transit metastases from squamous cell carcinoma penis." Indian Journal of Dermatology 57, no. 4 (2012): 291. http://dx.doi.org/10.4103/0019-5154.97674.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Nan Tie, Emilia, Michael A. Henderson, and David E. Gyorki. "Management of in‐transit melanoma metastases: a review." ANZ Journal of Surgery 89, no. 6 (2018): 647–52. http://dx.doi.org/10.1111/ans.14921.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Testori, A., S. Ribero, and V. Bataille. "Diagnosis and treatment of in-transit melanoma metastases." European Journal of Surgical Oncology (EJSO) 43, no. 3 (2017): 544–60. http://dx.doi.org/10.1016/j.ejso.2016.10.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Storey, Lucy, Mohammed Abdul-Latif, Sophia Kreft, et al. "Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases." Journal of Clinical Oncology 38, no. 15_suppl (2020): 10070. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10070.

Full text

Abstract:

10070 Background: In the context of multiple in-transit melanoma metastases without nodal involvement, a variety of treatment modalities have historically been employed including surgery, laser, isolated limb perfusion/infusion, intralesional interleukin-2, T-VEC and electrochemotherapy. Unfortunately, most patients treated with these modalities experience subsequent disease progression. While checkpoint inhibitors (CPI) are a standard of care for bulky unresectable stage III and for stage IV melanoma, patients with isolated in-transit metastases were rarely included in registration studies. T

APA, Harvard, Vancouver, ISO, and other styles

19

Tarantino, Giuseppe, Anne Zaremba, Tuulia Vallius, et al. "Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): e21518-e21518. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e21518.

Full text

Abstract:

e21518 Background: Patients with in-transit metastases (ITM) in melanoma are a heterogeneous subset of patients where melanoma recurrence is anatomically detected between the site of the primary tumor and the draining lymph node. Notably, a significant subset of those patients has locoregional recurrences with long-term survival without progression to distant sites. The underlying mechanisms responsible for these distinct phenotypes are unknown. Methods: To understand the evolution from primary melanoma to in-transit and distant metastasis, we characterized the tumor and immune microenvironmen

APA, Harvard, Vancouver, ISO, and other styles

20

Barbosa, Joana, Miguel Coelho, Ricardo Vieira, and Victor Farricha. "Isolated Limb Perfusion for the Treatment of Unresectable In- Transit Metastases of Cutaneous Squamous Cell Carcinoma." Journal of the Portuguese Society of Dermatology and Venereology 79, no. 2 (2021): 159–61. http://dx.doi.org/10.29021/spdv.79.2.1305.

Full text

Abstract:

Squamous cell carcinoma (SCC) is the second most common non-melanoma skin cancer and its incidence has been increasing over the past decades. SCC in-transit metastases are rare and predict a poor prognosis. We present the case of a 69-year-old patient with a right lower leg SCC, surgically excised with free margins. One month later, erythematous to violaceous, firm papules begin to erupt on the right lower leg, evolving to ulcerated nodules over a period of weeks. Homolateral inguinal and iliac nodal metastases were documented by percutaneous biopsy of an inguinal palpable lymph node and later

APA, Harvard, Vancouver, ISO, and other styles

21

El Moheb, Mohamad, Susan Kim, Chunyan Cao, et al. "Characterization of driver oncogenic mutations of in-transit melanoma metastases." Journal of Clinical Oncology 42, no. 16_suppl (2024): 9586. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.9586.

Full text

Abstract:

9586 Background: In-transit melanoma (ITM) is a distinctive form of melanoma metastasis, marked by aggressive locoregional progression and characterized by the entrapment of tumor cells within the lymphatic channels before reaching regional lymph nodes (LN). The mechanisms leading to lymphatic trapping rather than progression to distant metastasis are not well-understood. Previous research indicates a clonal origin for ITM, suggesting specific early-stage genetic alterations may drive this clinical phenotype. In this study, we sought to identify driver oncogenic mutations specific to ITM that

APA, Harvard, Vancouver, ISO, and other styles

22

Cohen, Max H., and Ronald B. Herberman: Deceased. "Skin test results with common and melanoma antigens compared to clinical outcomes of melanoma patients treated with intralesional (IL) dinitrochorobenzene (DNCB) or IL bacillus Calmette-Guerin (BCG)." Journal of Clinical Oncology 35, no. 7_suppl (2017): 59. http://dx.doi.org/10.1200/jco.2017.35.7_suppl.59.

Full text

Abstract:

59 Background: In a previous study involving in vitro serial testing in patients receiving IL BCG or IL DNCB we determined that measurements of serial in vitro phytohemagglutinin stimulation levels correlated with the patients’ clinical courses. The current evaluation attempted to determine which in vivo skin test studies were useful in this setting. Methods: All patients had locally progressive melanoma satellosis, or in-transit metastases, but no evidence of distant metastasis past regional lymph nodes. Patients had been randomized to repeatedly receive either IL BCG (9 patients), or IL DNCB

APA, Harvard, Vancouver, ISO, and other styles

23

Russano, Francesco, Marco Rastrelli, Luigi Dall’Olmo, et al. "Therapeutic Treatment Options for In-Transit Metastases from Melanoma." Cancers 16, no. 17 (2024): 3065. http://dx.doi.org/10.3390/cancers16173065.

Full text

Abstract:

In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM. Methods include a comprehensive review of clinical studies examining the impact of treatments like immune checkpoint

APA, Harvard, Vancouver, ISO, and other styles

24

Hayes, A. J., M. A. Clark, M. Harries, and J. M. Thomas. "Management of in-transit metastases from cutaneous malignant melanoma." British Journal of Surgery 91, no. 6 (2004): 673–82. http://dx.doi.org/10.1002/bjs.4610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Testori, Alessandro, Mark B. Faries, John F. Thompson, et al. "Local and intralesional therapy of in-transit melanoma metastases." Journal of Surgical Oncology 104, no. 4 (2011): 391–96. http://dx.doi.org/10.1002/jso.22029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Feeney, Kendra J., and Michael J. Mastrangelo. "Intralesional Therapy for In-transit and Satellite Metastases in Melanoma." Surgical Oncology Clinics of North America 24, no. 2 (2015): 299–308. http://dx.doi.org/10.1016/j.soc.2014.12.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lyle, Megan, and Georgina V. Long. "Diagnosis and Treatment ofKIT-Mutant Metastatic Melanoma." Journal of Clinical Oncology 31, no. 26 (2013): 3176–81. http://dx.doi.org/10.1200/jco.2013.50.4662.

Full text

Abstract:

A 52-year-old man has unresectable locally recurrent melanoma of the left foot ( Fig 1 ) and pulmonary metastases. Nine months before this presentation, he underwent a wide local excision and sentinel node biopsy for an acral melanoma on his left heel. Pathology disclosed Breslow thickness of 4.8 mm, Clark level IV, and tumor ulceration with a mitotic rate of 37 mitoses/mm2. Both sentinel nodes in the left groin were positive for melanoma cells, which expressed S100, HMB45, and melan A. At subsequent left inguinal dissection, seven more nodes showed no additional nodal metastases. Within 3 mon

APA, Harvard, Vancouver, ISO, and other styles

28

Thompson, John F., Robyn P.M. Saw, Johanna M. Dalton, et al. "Treatment of in-transit melanoma metastases using intralesional PV-10." Melanoma Research 31, no. 3 (2021): 232–41. http://dx.doi.org/10.1097/cmr.0000000000000729.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Eggermont, A. M. M., and P. M. Schlag. "Treatment of melanoma in-transit metastases confined to the limb." European Surgery 28, no. 1 (1996): 9–13. http://dx.doi.org/10.1007/bf02625948.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Royal, Richard Eldon, Luis M. Vence, Tara Wray, et al. "A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9582. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9582.

Full text

Abstract:

9582 Background: Toll like receptor (TLR) agonists may enhance vaccination or direct immune activation at the tumor microenvironment. This trial evaluates the biologic and clinical effects of Resiquimod, a TLR 7/8 agonist that can activate both myeloid (mDC, TLR 8) and plasmacytoid (pDC, TLR 7) dendritic cells, in patients with advanced stage melanoma. Methods: Class I HLA-A0201+ subjects with in-transit melanoma metastases or high risk for recurrence were vaccinated weekly with peptide vaccination (class I restricted peptide GP100209-2m and, if HLA-DP4+, also with class II restricted peptide

APA, Harvard, Vancouver, ISO, and other styles

31

Tian, Jiabao, and Camelia Quek. "Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses." International Journal of Molecular Sciences 25, no. 8 (2024): 4243. http://dx.doi.org/10.3390/ijms25084243.

Full text

Abstract:

Melanoma is the leading cause of global skin cancer-related death and currently ranks as the third most commonly diagnosed cancer in Australia. Melanoma patients with in-transit metastases (ITM), a type of locoregional metastasis located close to the primary tumor site, exhibit a high likelihood of further disease progression and poor survival outcomes. Immunotherapies, particularly immune checkpoint inhibitors (ICI), have demonstrated remarkable efficacy in ITM patients with reduced occurrence of further metastases and prolonged survival. The major challenge of immunotherapeutic efficacy lies

APA, Harvard, Vancouver, ISO, and other styles

32

Suojärvi, Nora J., Tiina A. Jahkola, Susanna Virolainen, Suvi K. Ilmonen, and Micaela M. Hernberg. "Outcome following local recurrence or in-transit metastases in cutaneous melanoma." Melanoma Research 22, no. 6 (2012): 447–53. http://dx.doi.org/10.1097/cmr.0b013e32835a310c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Hwang, Shelley J. E., Benjamin Y. Kong, Shaun Chou, Deepal Wakade, Matteo S. Carlino, and Pablo Fernandez-Penas. "Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis." Case Reports in Medicine 2017 (2017): 1–3. http://dx.doi.org/10.1155/2017/5462929.

Full text

Abstract:

There are reported cases of diphencyprone used in treating cutaneous metastases of melanoma. Here, we report a patient with previous primary melanoma on his left back treated with surgical excision and lymphadenectomy, followed by radiotherapy for the recurrent tumor on the primary site. Despite radiotherapy and treatment with dabrafenib and trametinib, in-transit metastases have developed and topical diphencyprone was applied to these metastases. Six weeks later, the patient developed fever and a spreading erythematous tender indurated plaque covering the left side of the body including axill

APA, Harvard, Vancouver, ISO, and other styles

34

Petrochenko, N. S., T. K. Kharatishvili, A. K. Valiev, et al. "Long-term results of isolated limb perfusion with hyperthermia in patients with limb melanoma." Bone and soft tissue sarcomas, tumors of the skin 15, no. 1 (2023): 38–43. http://dx.doi.org/10.17650/2219-4614-2023-15-1-38-43.

Full text

Abstract:

Introduction. In patients with local recurrences of melanoma or with transit metastases of this tumor located distal to the axilla and inguinal region, the use of isolated regional limb perfusion is considered as one of the effective treatment options.Aim. To evaluate the long-term results of treatment extremities melanoma using the method of isolated regional perfusion of the extremities.Materials and methods. An analysis of the treatment and observation results of 72 patients (12 men and 60 women) with melanoma of the extremities was carried out, the median age was 56.7 years (from 25 to 78

APA, Harvard, Vancouver, ISO, and other styles

35

Mondal, Krishnendu, and Rupali Mandal. "Nodular melanoma on lip with retrograde in-transit metastases on face." Indian Journal of Dermatology, Venereology and Leprology 87 (July 1, 2021): 687–89. http://dx.doi.org/10.25259/ijdvl_64_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Read, Rebecca L., Lauren Haydu, Robyn P. M. Saw, et al. "In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy." Annals of Surgical Oncology 22, no. 2 (2014): 475–81. http://dx.doi.org/10.1245/s10434-014-4100-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Beasley, Georgia, and Douglas Tyler. "In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy." Annals of Surgical Oncology 22, no. 2 (2014): 358–60. http://dx.doi.org/10.1245/s10434-014-4110-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Blackmon, Jonathan T., Michael S. Stratton, Young Kwak, et al. "Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec." JAAD Case Reports 3, no. 4 (2017): 280–83. http://dx.doi.org/10.1016/j.jdcr.2017.02.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tkachenko, Elizabeth, Jennifer Y. Lin, and Rebecca I. Hartman. "Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases." JAAD Case Reports 5, no. 5 (2019): 427–29. http://dx.doi.org/10.1016/j.jdcr.2019.03.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Teng, Edward, Gloria R. Sue, Rajendra Sawh-Martinez, et al. "Scalp Melanoma and In-transit Metastases: A Retrospective Case-controlled Study." American Surgeon 80, no. 12 (2014): 1272–74. http://dx.doi.org/10.1177/000313481408001233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

MOHS, FREDERIC E. "Micrographic Surgery for Satellites and In-Transit Metastases of Malignant Melanoma." Journal of Dermatologic Surgery and Oncology 12, no. 5 (1986): 471–76. http://dx.doi.org/10.1111/j.1524-4725.1986.tb01936.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Kirov, K., E. Peycheva, and I. Gavrilova. "P024. Electro-immunotherapy with BCG of superficial in-transit melanoma metastases." Melanoma Research 21 (June 2011): e29-e30. http://dx.doi.org/10.1097/01.cmr.0000399485.18517.4b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Constantinescu, Anna, Roger Olofsson Bagge, and Anne Huibers. "Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis." Journal of Clinical Oncology 43, no. 16_suppl (2025): 9565. https://doi.org/10.1200/jco.2025.43.16_suppl.9565.

Full text

Abstract:

9565 Background: Isolated limb perfusion (ILP) is a regional treatment for patients with melanoma in-transit metastases (ITM) confined to extremities, using a high dose of melphalan. ILP has a high response rate, with approximately 60% having a complete response (CR). This study aimed to validate if pre-operative immunological phenotype could be a predictive factor for CR after ILP. Methods: A total of 132 patients undergoing ILP as a first treatment for melanoma ITM between January 2012 and March 2023 were included in this study. The number and percentage of naïve and memory T and B cell subt

APA, Harvard, Vancouver, ISO, and other styles

44

Deroose, Jan P., Dirk J. Grünhagen, Alexander M. M. Eggermont, and Cornelis Verhoef. "Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases." Melanoma Research 25, no. 5 (2015): 427–31. http://dx.doi.org/10.1097/cmr.0000000000000177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Marsden, J. "Management of in-transit limb metastases in melanoma: state of the art." Melanoma Research 20 (June 2010): e11-e12. http://dx.doi.org/10.1097/01.cmr.0000382767.08743.d0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bagge, A. S. Lindqvist, D. Katsarelias, and R. Olofsson Bagge. "Quality of life in patients with in-transit metastases of malignant melanoma." European Journal of Surgical Oncology 45, no. 2 (2019): e133-e134. http://dx.doi.org/10.1016/j.ejso.2018.10.456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gaudy, Cardine, Marie-Aleth Richard, Gilles Folchetti, Jean Jacques Bonerandi, and Jean-Jacques Grob. "Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma." Journal of Cutaneous Medicine and Surgery 10, no. 3 (2006): 115–21. http://dx.doi.org/10.2310/7750.2006.00037.

Full text

Abstract:

Background: Electrochemotherapy (ECT) combines intralesional injections of bleomycin with electroporation (EP), which permeabilizes tumor cells and thus increases the bleomycin efficacy at the tumor site. Objective: To assess whether EP therapy improves the local control of skin metastases of melanoma by intralesional bleomycin. The secondary objective was to evaluate tolerance of the treatments. Patients: Patients with at least two measurable skin metastases of melanoma that were previously untreated, either in stage III with in-transit melanoma skin metastases or stage IV with no efficacy of

APA, Harvard, Vancouver, ISO, and other styles

48

Lenga, Marisa, Esther Choi, Jeffrey Sosman, et al. "Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy." Journal for ImmunoTherapy of Cancer 12, no. 11 (2024): e009581. http://dx.doi.org/10.1136/jitc-2024-009581.

Full text

Abstract:

In-transit metastases of malignant melanoma pose a significant clinical challenge, particularly in patients with contraindications to systemic therapies. While surgical excision and systemic immunotherapies remain standard treatments, localized therapies such as intralesional talimogene laherparepvec (T-VEC) and topical imiquimod, which stimulate tumor-specific T-cell responses, have garnered increasing attention for their potential efficacy and tolerability. Although the individual efficacy of these therapies is well-documented, their combined use and their synergistic effects have not been w

APA, Harvard, Vancouver, ISO, and other styles

49

Wain, E. M., N. K. Webber, C. M. Stefanato, P. Banerjee, and S. L. Morris. "Multiple in-transit cutaneous metastases from a primary cutaneous squamous cell carcinoma." Clinical and Experimental Dermatology 34, no. 4 (2009): 522–24. http://dx.doi.org/10.1111/j.1365-2230.2008.02967.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Teng, E., S. Nishikawa, R. Sawh, et al. "150: SCALP MELANOMAS AND IN-TRANSIT METASTASES: A RETROSPECTIVE CASE-CONTROLLED STUDY." Plastic and Reconstructive Surgery 127 (May 2011): 83. http://dx.doi.org/10.1097/01.prs.0000396837.90492.cd.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!